
Therapeutic indications in chronic lymphocytic leukemia. Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries, while it is rare in Asia. It is defined by the presence of more than 5 G/L of B cell clonal. If its evolution is very heterogeneous, the treatment required in the active forms of the disease, progressive stages A and B and stage C of the classification of Binet, benefited in recent years of considerable progress. We consider in this paper the treatment of CLL front line and in patients with relapsed or refractory (R/R), with or without inactivation of TP53: deletion or del(17p) and/or mutations of the TP53 gene. We will discuss the place of immunochemotherapy, including the choice of anti-CD20 monoclonal antibodies: rituximab, ofatumumab or obinutuzumab. For BCR inhibitors, we will limit to the most mature drugs that have obtained marketing authorization: inhibitors of Bruton tyrosine kinase (BTK) ibrutinib and phosphatidyinositol 3-kinase (PI3K) delta, idelalisib. Given its impact, research inactivation of TP53 should be performed before each line of therapy, his presence modifying therapeutic strategies. The treatments, if properly codified, must consider the often little known side effects, whose management is complex.